AIMI Company Report

Analyst Coverage

Research analysts covering AIMI.

Recent press releases and 8-K filings for AIMI.

AIM ImmunoTech Prioritizes Pancreatic Cancer for Ampligen Development

AIMI

New Projects/Investments

Revenue Acceleration/Inflection

AIM ImmunoTech (AIMI) is strategically prioritizing pancreatic cancer as the lead indication for its drug Ampligen, citing a significant unmet medical need, the potential for substantial biotech deals, and existing orphan drug designations in the United States and Europe.
Ampligen has demonstrated the ability to extend overall survival as a monotherapy in pancreatic cancer and shows a synergistic impact when combined with AstraZeneca's Durvalumab (Imfinzi) in ongoing Phase 2 trials.
The company's clinical and regulatory strategy aims to advance Ampligen to a Phase 3 trial in pancreatic cancer, preferably in collaboration with a major pharmaceutical partner, to establish its therapeutic impact beyond current standards of care.
A key upcoming milestone is the year-end report from the Phase 2 study with Durvalumab in pancreatic cancer, which is expected to be positive and serve as an inflection point for the company.

Dec 4, 2025, 9:00 PM

AIM ImmunoTech discusses Ampligen's immuno-oncology focus and pancreatic cancer strategy

AIMI

New Projects/Investments

Guidance Update

AIM ImmunoTech's lead asset, Ampligen, is presented as a drug with significant potential in immuno-oncology, functioning both as a monotherapy and as a synergistic enhancer with checkpoint inhibitors across various solid tumors.
The company has strategically prioritized pancreatic cancer as its lead indication, citing a substantial unmet medical need, significant business opportunity, and existing orphan drug designations and patents for Ampligen in this area.
Clinical trial data indicates Ampligen's ability to extend overall survival as a monotherapy in pancreatic cancer and demonstrates a synergistic effect when combined with AstraZeneca's durvalumab (Imfinzi) in a Phase II study.
A year-end report on the Phase II study of Ampligen with durvalumab in pancreatic cancer is anticipated soon, which is considered a crucial milestone for the company's future development and commercialization strategy.
AIM ImmunoTech's strategy involves securing a big pharma partner to advance Ampligen into a Phase III trial for pancreatic cancer, leveraging promising data and market exclusivity.

Dec 4, 2025, 9:00 PM

AIM ImmunoTech Discusses Strategic Focus on Pancreatic Cancer and Ampligen Development

AIMI

New Projects/Investments

M&A

AIM ImmunoTech's lead asset, Ampligen, is being developed for immuno-oncology, with a strategic focus on pancreatic cancer as its lead indication.
Ampligen has shown potential as a monotherapy and as a synergistic enhancer with checkpoint inhibitors like Merck's Keytruda and AstraZeneca's Durvalumab (Imfinzi) in various solid tumors, including pancreatic cancer.
The company prioritizes pancreatic cancer due to the high unmet medical need (over 500,000 deaths worldwide annually) and market exclusivity provided by orphan drug designations in the U.S. and Europe, as well as a U.S. patent for Ampligen plus PD-L1 checkpoint inhibitors.
AIM ImmunoTech's clinical strategy for pancreatic cancer involves advancing to a Phase 3 trial, ideally with a large pharmaceutical partner, following promising Phase 2 data with Durvalumab.
A key upcoming milestone is the year-end report from Erasmus Medical Center on the Phase 2 study of Ampligen with Durvalumab in pancreatic cancer, expected by year-end 2025 or early January 2026.